Published in J Urol on December 01, 1988
Screening for prostate cancer. How can patients give informed consent? Can Fam Physician (1993) 1.01
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA (1993) 3.41
Indwelling ureteral stents as definitive therapy for distal ureteral calculi. J Urol (1995) 2.28
Commissary tobacco sales: the elimination of a historic artifact. Mil Med (1995) 2.00
The teaching of legal medicine in British medical schools. Med Educ (1986) 1.87
Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol (1990) 1.83
Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutr Cancer (2001) 1.69
Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology (1976) 1.67
Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA (1995) 1.62
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol (2008) 1.55
Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol (1995) 1.47
The urology residency matching program in practice. J Urol (2000) 1.46
Assessment of endpoints for clinical trials for localized prostate cancer. Urology (1997) 1.45
Testicular cancer in blacks. A multicenter experience. Cancer (1994) 1.42
SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol (2001) 1.42
A METHOD OF OUTLINING CUTANEOUS NERVE ARES. Science (1933) 1.39
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl (2008) 1.31
SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis (2000) 1.30
Color vision deficits during laser lithotripsy using safety goggles for coumarin green or alexandrite but not with holmium:YAG laser safety goggles. J Urol (1998) 1.30
Economic impact of urolithiasis in the United States. J Urol (1995) 1.24
ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res (2008) 1.22
Malignant degeneration of cryptorchid testes following orchiopexy. J Urol (1974) 1.21
Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol (2000) 1.20
Economics of screening for carcinoma of the prostate. Urol Clin North Am (1990) 1.17
Flare Associated with LHRH-Agonist Therapy. Rev Urol (2001) 1.16
Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J (1998) 1.09
Impact of routine screening for adenocarcinoma of the prostate on stage distribution. J Urol (1987) 1.08
On Premedical Education. Cal West Med (1932) 1.07
Prevalence of BPH and lower urinary tract symptoms in West Africans. Prostate Cancer Prostatic Dis (2011) 1.07
Lest we abandon digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst (1998) 1.07
The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol (1987) 1.07
Urolithiasis in childhood: the significance of oxaluria. Case reports. Mo Med (1967) 1.06
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control (2001) 1.04
Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol (1998) 1.03
Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol (2000) 1.03
Direct vision bladder catheterization using a short rigid ureteroscope. Urology (1998) 1.03
Quality of life assessment in Southwest Oncology Group trials. Oncology (Williston Park) (1990) 1.00
Surgical treatment of carcinoma of the male urethra. Urol Clin North Am (1992) 1.00
Hypospadias: a contemporary epidemiologic assessment. Urology (2001) 1.00
Adenocarcinoma of the prostate: results of routine urological screening. J Urol (1984) 0.99
PSA screening--current controversy. Ann Oncol (1998) 0.98
Leiomyomatous vesical outlet obstruction. Urology (1974) 0.97
Meta-analysis of the literature: guideline development for prostate cancer treatment. American Urological Association Prostate Cancer Guideline Panel. J Urol (1994) 0.96
Expectant management of localized prostatic cancer. Cancer (1991) 0.95
Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl (2008) 0.94
Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. Prostate (2008) 0.92
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol (2003) 0.92
Effects of lactation and pregnancy on gene expression of endometrium of Holstein cows at day 17 of the estrous cycle or pregnancy. J Dairy Sci (2012) 0.90
Efficacy and morbidity of "channel" TURP. Urology (1991) 0.90
Managing the Foley catheter. Am Fam Physician (1993) 0.89
Morbidity and mortality following radical prostatectomy: a national analysis of Civilian Health and Medical Program of the Uniformed Services beneficiaries. J Urol (1995) 0.89
A pityriasis rosea-like eruption secondary to bacillus Calmette-Guérin therapy for bladder cancer. Cutis (1996) 0.89
Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma? Urology (2001) 0.87
Effect of heat stress during the dry period on mammary gland development. J Dairy Sci (2011) 0.87
Prostate Cancer Prevention Trial (PCPT) update. Eur Urol (1999) 0.86
Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. Urology (1997) 0.86
Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology (1995) 0.84
Disappearance of well-differentiated carcinoma of the prostate: effect of transurethral resection of the prostate, prostate-specific antigen, and prostate biopsy. Urology (2001) 0.84
Renal tumors in young adults. Urology (1992) 0.84
The effects of various manipulations on serum phosphatase levels in benign disease. J Urol (1974) 0.83
Renal medullary carcinoma: can early diagnosis lead to long-term survival? J Urol (2000) 0.83
Automated entry of hospital infection surveillance data. Infect Control Hosp Epidemiol (1997) 0.83
Papillary "tumours" of the left ventricle. Br Heart J (1967) 0.83
Effect of late-gestation maternal heat stress on growth and immune function of dairy calves. J Dairy Sci (2012) 0.83
The histologic effects of dilation and internal urethrotomy on the canine urethra. J Urol (1970) 0.82
Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst (1994) 0.82
The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol (1997) 0.82
Sterilization and disinfection in general practice in Northern Ireland. J Hosp Infect (1999) 0.82
Urological aspects of chylous ascites. Case report. Mo Med (1971) 0.81
Association of tobacco use and periapical pathosis - a systematic review. Int Endod J (2012) 0.81
Partner notification of sexually transmitted disease in an obstetric and gynecologic setting. Obstet Gynecol (1999) 0.81
Reduction of length of stay and cost of transurethral resection of the prostate by early catheter removal. Br J Urol (1996) 0.80
Long-term results of bladder flap repair of ureteral injuries. J Urol (1974) 0.80
Morbidity with contemporary prostate biopsy. J Urol (1993) 0.80
Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma. J Cancer Res Clin Oncol (1994) 0.80
Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer (1988) 0.80
Endovascular AAA repair in a patient with a horseshoe kidney and an isthmus mass. J Endovasc Ther (2001) 0.79
Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol (1995) 0.79
Clinical experience with renal capsule flap pyeloplasty. J Urol (1969) 0.79
Epididymal rhabdomyoma. J Urol (2000) 0.79
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. South Med J (1998) 0.79
Re: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol (2001) 0.79
Bladder carcinoma presenting as exercise-induced hematuria. Postgrad Med (1988) 0.79
Screening for carcinoma of the prostate: efficacy of available screening tests. World J Surg (1989) 0.79
The fate of buried vaginal epithelium. J Urol (1992) 0.79
Effect of cooling heat-stressed dairy cows during the dry period on insulin response. J Dairy Sci (2012) 0.79
Prostatism and inguinal hernia. South Med J (1982) 0.78
Chemoprevention of prostate cancer. Urology (1994) 0.78
Intravesical alum irrigation for intractable bleeding secondary to adenocarcinoma of the prostate. J Urol (1987) 0.78
Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder. Urology (1993) 0.78
Complete urinary obstruction following periurethral polytetrafluoroethylene injection for urinary incontinence. J Urol (1989) 0.78
Problems associated with Gibbons ureteral catheter. Urology (1976) 0.78
Magnetism as an aid to a prosthetic problem. Br J Oral Surg (1964) 0.78
An analysis of factors affecting survival in 150 patients with renal carcinoma. J Urol (1975) 0.77
Lactation Biology Symposium: effects of photoperiod on mammary gland development and lactation. J Anim Sci (2011) 0.77
Radiographic characteristics of the vesicourethral anastomosis after radical retropubic and perineal prostatectomy. Mil Med (1998) 0.77
Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer Biother (1995) 0.77